Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum
June 11 2020 - 06:30AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
its participation in the JMP Securities Hematology & Oncology
Forum (Virtual). Troy Wilson, Ph.D., J.D., President and Chief
Executive Officer, is scheduled to participate in a fireside chat
on Thursday, June 18, 2020 at 10:40 a.m. ET / 7:40 a.m. PT. The
virtual forum will be held from June 18-19, 2020.
A live audio webcast of the fireside chat will be available in
the Investors section of Kura’s website at www.kuraoncology.com,
with an archived replay available for 30 days following the
event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The Company’s pipeline consists of two wholly
owned small molecule drug candidates that target cancer signaling
pathways where there is a strong scientific and clinical rationale
to improve outcomes by identifying those patients most likely to
benefit from treatment. Kura’s most advanced drug candidate is
tipifarnib, a potent, selective and orally bioavailable farnesyl
transferase inhibitor currently in a registration-directed trial in
patients with recurrent or metastatic HRAS mutant head and neck
squamous cell carcinoma. The Company’s pipeline is also highlighted
by KO-539, a potent and selective inhibitor of the menin-KMT2A(MLL)
protein-protein interaction currently in a Phase 1/2A clinical
trial, KOMET-001, in patients with relapsed/refractory acute
myeloid leukemia. For additional information about Kura, please
visit the Company’s website at www.kuraoncology.com.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke ICR(858)
356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2023 to Mar 2024